News
Portfolio Company News
- May 23, 2013
BioWorld Today: News to Note-Veloxis Pharmaceuticals A/S - May 23, 2013
BioWorld Today: Clinic Roundup-Ceregene Inc.
- May 23, 2013
BioWorld Today: Clinic Roundup--ChemoCentryx, Inc.
- May 23, 2013
BioWorld Today: Clinic Roundup--MacroGenics, Inc. - May 21, 2013
BioWorld Today: Clinic Roundup-Veloxis Pharmaceuticals A/S - May 17, 2013
BioWorld Today: Clinic Roundup--Chimerix Inc. - May 16, 2013
BioWorld Today: Financings Roundup-- Kite Pharma Inc. - May 11, 2013
BioWorld Today: News to Note--Flamel Technologies Inc. - May 09, 2013
Trevena Inc. and Forest Laboratories Announce Development Collaboration For TRV027
- May 08, 2013
Portola Announces Its Factor Xa Inhibitor Antidote PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of the Anticoagulant Activity of Eliquis® in Phase II Study
- May 07, 2013
Ablynx Starts Pre-Clinical Development of ALX-0962, an Anti-IgE Nanobody, to Treat Severe Allergic Asthma
- May 02, 2013
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
- May 02, 2013
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43
- May 02, 2013
Insulet to Develop New Version of the OmniPod Insulin Pump for Use With Humulin R U-500
Concentrated Insulin for People With Type 2 Diabetes
- April 29, 2013
Cara Therapeutics Enters Into Development and Commercial Alliance with Maruishi for Novel Kappa Opioid Agonist, CR845, in Japan
- April 29, 2013
Chimerix Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With
Life-Threatening Viral Infections
- April 29, 2013
Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patients
- April 25, 2013
Scynexis Presents SCY‐635 Data on HCV at International Liver Congress
- April 24, 2013
Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin
- April 24, 2013
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase II Clinical Trial
< Previous
